Brittany Lovely

Managing Editor, OncLive®
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: blovely@mjhassoc.com

Articles

Nab-paclitaxel Plus Gemcitabine Boosts Survival for Pancreatic Cancer in 5-year Follow-Up

July 29th 2021

Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.

Triplet Combination Demonstrates Promise for Frontline Treatment of BRAF V600E–mutant CRC

July 28th 2021

Doublet and triplet chemotherapy-based therapies are standard treatment options for patients with BRAF V600–mutant metastatic colorectal cancer.

Apalutamide Plus ADT Improves Survival Regardless of Disease Volume in mCSPC

July 12th 2021

Investigators demonstrated that the benefit of androgen deprivation therapy was extended with the addition of apalutamide for patients with metastatic castration-sensitive prostate cancer regardless of disease volume.

Novel Combination May Break Outcomes Stalemate in Pancreatic Cancer

July 7th 2021

Therapeutic breakthroughs for patients with metastatic pancreatic cancer have eluded investigators for decades, with chemotherapeutic combination strategies serving as the insurmountable standard of care.

Oncology Leaves Its Mark on 2020 Research and Development Trends

June 16th 2021

Rates of clinical trial initiation, novel drug development, and collaborative research and development deals were oncology.

ADCs Show Promise in NSCLC But Have a Long Road Ahead

June 14th 2021

The potential role for antibody-drug conjugates for treating patients with non–small cell lung cancer continues to evolve as new data challenge investigators to reexamine their approaches.

Trastuzumab Deruxtecan Maintains Antitumor Activity in HER2+ mCRC

June 7th 2021

Final results of the DESTINY-CRC01 trial were consistent with primary analysis, establishing the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-overexpressing metastatic colorectal cancer.

Adjuvant Gefitinib Fails to Outshine Chemo in EGFR+ NSCLC

June 6th 2021

Adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer. However, the EGFR inhibitor did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

Liposomal Irinotecan Combo Improves Outcomes for Patients with Biliary Tract Cancer

June 5th 2021

Data from the phase 2 NIFTY trial demonstrated that liposomal irinotecan in combination with 5-fluorouracil/leucovorin significantly improved progression-free survival and overall survival for patients with metastatic biliary tract cancer whose disease had progressed following first-line line gemcitabine/cisplatin.

Afami-cel Elicits Durable Response Rates in Patients With Synovial Sarcoma or MRCLS

June 4th 2021

Encouraging initial durability has been observed with afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma, according to data from the phase 2 SPEARHEAD-1 trial.

Novel Triplets Shed New Light on Sequencing in Relapsed/Refractory Myeloma

May 5th 2021

New triplet combinations anchored by anti-CD38 antibodies are expanding the therapeutic landscape for relapsed or refractory multiple myeloma, providing exciting options that extend progression-free survival windows from months to years for heavily pretreated patients.

Phase 1/2 Studies Set the Stage for Targeted Combos in B-Cell Lymphomas

April 27th 2021

Although chemotherapy is not likely to lose its place in the frontline treatment of patients with B-cell lymphomas, encouraging data from early-phase studies evaluating the use of targeted agents in combination with and without chemotherapy are capturing the interest of investigators in the field.

Dabrafenib Plus Trametinib Provides Benefit Across Glioma Subtypes

April 12th 2021

Dual inhibition of the MAPK pathway using the BRAF and MEK inhibitors dabrafenib and trametinib, respectively, resulted in durable clinical benefit for patients with BRAF V600E mutant low- and high-grade glioma.

Future Is Wide Open for HER2+ Breast Cancer

April 12th 2021

As longer-term follow-up data become available for several agents approved for HER2-positive metastatic breast cancer, investigators are looking closely at the characteristics of patients enrolled in those clinical trials to determine appropriate treatment strategies in the third-line setting and beyond.

Experts Take Stock of New CNS Data for HER2+ Metastatic Breast Cancer

March 18th 2021

Findings from recent analyses have kindled hope that novel agents with manageable toxicity profiles may begin to bridge the gap for patients with HER2-positive metastatic breast cancer.

Personalizing HER2-Targeted Treatment Strategies in Early-Stage and Advanced Breast Cancer

March 5th 2021

Debu Tripathy, MD, discusses some of the unanswered clinical questions that remain for patients with HER2-positive disease and some strategies for personalizing treatment in the neoadjuvant and adjuvant settings.

CONFIRM Data Push Nivolumab into Treatment Landscape for Relapsed Mesothelioma

January 30th 2021

January 30, 2021 - Data from the phase 3 CONFIRM trial support single-agent nivolumab as an effective treatment approach for patients with previously treated malignant mesothelioma.

HER2-Directed Antibody-Drug Conjugates May Carve Out a Place in NSCLC Landscape

January 21st 2021

The current standard of care for patients with non–small cell lung cancer does not include therapies targeting HER2, a mutation that occurs in up to 4% of cases. However, data from recent studies of antibody-drug conjugates directed at HER2 activity are generating excitement about the potential utility of ADCs in this space.

Boehringer Ingelheim Looks to Expand Targeted Therapies Portfolio

January 5th 2021

January 5, 2020 - Boehringer Ingelheim will add to its cancer cell-directed therapies portfolio with the acquisition of NBE-Therapeutics, the developer of NBE-002, an anti-ROR1 antibody-drug conjugate.

AI-Based Analysis Enhances Prediction of Best Responders for Trastuzumab Deruxtecan

December 11th 2020

December 11, 2020 - Use of a novel HER2 quantitative continuous score was better able to provide an objective and quantitative assessment of HER2 expression to identify patients who are most likely to respond to fam-trastuzumab deruxtecan-nxki.